Why does the myocardium fail? Insights from basic science

Lancet

Volumn 352, Issue SUPPL.1, 1998, Pages 8-14

  Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANGIOTENSIN; CALCIUM CHANNEL; CONTRACTILE PROTEIN; ENDOTHELIN; MYOSIN; PHOSPHOLIPASE C; RYANODINE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; BIOENERGY; CELL FUNCTION; CYTOSKELETON; GENE EXPRESSION; HEART CONTRACTION; HEART DILATATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SODIUM CALCIUM EXCHANGE;

EID: 0007436490     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90311-7     Document Type: Article

References (88)

1. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15.
2. Richardson P, McKenna W, Bristow MR, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-42.
3. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophie cardiomyopathy. N Engl J Med 1992; 326: 1108-14.
4. Milasin J, Francesco M, Severini GM, et al. A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet 1996; 5: 73-79.
5. Olson TM, Michels W, Thibodeau SN, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science (in press).
6. Durand J-B, Bachinski LL, Beiling LC, et al. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation 1995; 92: 3387-89.
7. Krajinovic M, Pinamonti B, Sinagra G, et al, and the Heart Muscle Disease Study Group. Linkage of familial dilated cardiomyopathy to chromosome 9. Am J Hum Genet 1995; 57: 846-52.
8. Olson TM, Keating MT. Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest 1996; 97: 528-32.
9. Raynolds MV, Bristow MR, Bush E, et al. Angiotensin converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-75.
10. Pinto YM, van Gilst WH, Kingma JH, Schunkert H, for the Captopril and Thrombolysis Study Investigators. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 1995; 25: 1622-26.
11. Zerjal T, Vatta M, Gregori D, et al. Genetic polymorphisms of the renin-angiotensin system in familial dilated cardiomyopathy. J Am Coll Cardiol 1998; 31 (suppl A): 350A.
12. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268: 23116-21.
13. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 10483-88.
14. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J 1995; 16 (suppl F): 20-31.
15. Ross J, Braunwald E. Studies of Starling's law of the heart IX. The effects of impeding venous return on performance of the normal and failing ventricle. Circulation 1964; 30: 719-27.
16. Schwinger RHG, Bohm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994; 74: 959-69.
17. Holubarsch C, Thorsten R, Goldstein DJ, et al. Existence of the Frank-Starling mechanism in the failing human heart: investigations on the organ, tissue, and sarcomere levels. Circulation 1996; 94: 683-89.
18. Feldman MD, Gwathmey JK, Phillips P, Schoen F, Morgan JP. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol 1988; 3: 273-83.
19. Muleiri LA, Hasenfuss G, Ittleman F, et al. Altered myocardial force-frequency relationship in the human heart failure. Circulation 1992; 85: 1743-50.
20. Cohn JN. Structural basis for heart failure: ventricular remodeling an its pharmacological inhibition. Circulation 1995; 91: 2504-07.
21. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995; 92: 2540-49.
22. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80 (11A): 26L-40L.
23. Nascimben L, Ingwall JS, Pauletto P, et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation 1996; 94: 1894-901.
24. Tsutsui H, Ishihara K, Cooper G W. Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium. Science 1993; 260: 682-87.
25. Bristow MR, Ginsburg R, Minobe WA, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982; 307: 205-11.
26. 1 receptor down-regulation in heart failure. Circ Res 1986; 59: 297-309.
27. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 1986; 8: 1235-42.
28. 2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989; 35: 295-303.
29. Bristow MR, Anderson FL, Port JD, et al. Differences in β-adrenergic neuroeffector mechanisms in ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991; 84: 1024-39.
30. 1-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454-63.
31. r 40 000 pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988; 82: 189-97.
32. 1-proteins in heart failure. Lancet 1988; ii: 936-37.
33. iα in right and left ventricular failure. J Mol Cell Cardiol 1994; 26: 133-49.
34. Bristow MR, Minobe W, Rasmussen R, et al. α-adrenergic neuroeffector abnormalities in the failing human heart are produced by local, rather than systemic mechanisms. J Clin Invest 1992; 89: 803-15.
35. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986; 74: 1290-302.
36. Colucci WS, Denniss AR, Leatherman GF, et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest 1988; 81: 1103-10.
37. White M, Yanowitz F, Gilbert EM, et al. Role of beta-adrenergic receptor downregulation in the peak exercise response of patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995; 76: 127.
38. Binkley PF, Nunziata E, Haas GH, Nelson SD, Cody RJ. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 1991; 18: 464-72.
39. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of β-adrengic antagonists. Mol Pharm 1994; 45: 490-99.
40. 2-adrenergic receptor. Science 1994; 264: 562-66.
41. Luo W, Grupp IL, Ponniah S, et al. Targeted ablation of the phospholamban gene is associated wtih markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 1994; 75: 401-09.
42. Anand IS, Liu D, Chugh SS, et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 1997; 96: 3974-84.
43. Gerdes AM, Kellerman SE, Moore JA, et al. Structural remodeling of cardiac myocytes from patients with chronic ischemic heart disease. Circulation 1992; 86: 426-30.
44. Zhang J, McDonald KM. Bioenergetic consequences of left ventricular remodeling. Circulation 1995; 92: 1011-19.
45. Sata M, Sugiura S, Yamashita H, Momomura S, Serizawa T. Coupling between myosin ATPase cycle and creatine kinase cycle facilitates cardiac actomyosin sliding in vitro: a clue to mechanical dysfunction during myocardial ischemia. Circulation 1996; 93: 310-17.
46. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335: 1182-89.
47. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart: myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68: 1560-68.
48. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94: 2285-96.
49. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96: 1976-82.
50. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 1998; 97: 1375-81.
51. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Ann Rev Physiol 1993; 55: 55-75.
52. Sadosha J, Izumo S. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: potential involvement of an autocrine/paracrine mehanism. EMBO J 1993; 12: 1681-92.
53. Teiger E, Dam T-V, Richard L, Wisnewsky C, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97: 2891-97.
54. Saez LJ, Gianola KM, McNally EM, Feghali A, Eddy A, Shows TB, et al. Human cardiac myosin heavy chain genes and their linkage in the genome. Nucleic Acids Res 1987; 15: 5443-59.
55. Kurabayashi M, Tsuchimochi H, Komuro I, Takaku F, Yazaki Y. Molecular cloning and characterization of human cardiac α- and β-form myosin heavy chain complementary cDNA clones. J Clin Invest 1988; 82: 524-31.
56. Clark WA, Chizzonite RA, Everett AW, Rabinowitz M, Zak R. Species correlations between cardiac isoenzymes: a comparison of electrophoretic and immunologic properties. J Biol Chem 1982; 257: 5449-54.
57. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic Cardiomyopathy. Circulation 1995; 92: 1336-47.
58. Barany M. ATPase activity of myosin correlated with speed of muscle shortening. J Gen Physiol 1967; 50: 197-218.
59. Morano M, Zacharzowski U, Maier M, et al. Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest 1996; 98: 467-73.
60. Anderson PAW, Malouf NN, Oakley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans: a comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991; 69: 1226-33.
61. Nadal-Ginard B, Mahdavi V. Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 1989; 84: 1693-700.
62. Nakao K, Minobe WA, Roden RL, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997; 100: 2362-70.
63. Hajjar RJ, Gwathmey JK. Cross-bridge dynamics in human ventricular myocardium. Circulation 1992; 86: 1819-26.
64. Pagani ED, Alousi AA, Grant AM, Older TM, Dziuban SW, Allen PD. Changes in myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, and mitral valve insufficiency. Circ Res 1988; 63: 380-85.
65. Jones WK, Grupp LL, Doetschman T, et al. Ablation of the murine α myosin heavy chain gene leads to dosage effects and functional defects in the heart. J Clin Invest 1996; 98: 1906-17.
66. αq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci 1997; 94: 8121-26.
67. Dorn GW, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol 1994; 36: H400-405.
68. Imamura S-I, Matsuoka R, Hiratsuka E, et al. Adaptational changes of MyHC gene expression and isoenzyme transition in cardiac overloading. Am J Physiol 1991; 260: H73-79.
69. 2+ handling in pressure overload hypertrophy. J Clin Invest 1997; 100: 1742-49.
70. Bristow MR, Gilbert EM, Lowes BD, et al. Changes in myocardial gene expression associated with β-blocker-related improvement in ventricular systolic function. Circulation 1997; 96: I-92.
71. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. β-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985; 17 (suppl 2): 41-52.
72. S and adenylyl cyclase activities in compensated left ventricular hypertrophy: in heart failure, only the impairment in adenylyl cyclase activation progresses. J Clin Invest 1991; 87: 293-98.
73. 1-adrenergic receptor. J Am Coll Cardiol 1998; 311 (suppl A): 177A.
74. Rockmam HA, Chien KR, Choi D-J, et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998; 95: 7000-05.
75. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79: 483-90.
76. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, LV functional, and anti-adrenergic effects of chronic treatment with metoprolol vs carvedilol in the failing heart. Circulation 1996; 94: 2817-25.
77. iα-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 1996; 51: 127-32.
78. 2+ ATPase increases myocardial performance. Circulation 1997; 96: I-138.
79. Kadambi VJ, Ponniah S, Harrer JM, et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996; 97: 533-39.
80. Beuckelmann DJ, Näbauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85: 1046-55.
81. Molkentin JD, Lu J-R, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 1-20.
82. Movsesian MA, Bristow MR, Krall J. Calcium uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 1989; 65: 1141-44.
83. Rasmussen RP, Minobe W, Bristow MR. Calcium antagonist binding sites in failing and non-failing human ventricular myocardium. Biochem Pharm 1990; 39: 691-96.
84. 2+-release channel (ryanodine receptor) in human failing myocardium. Europ J Cardiol 1997; 18: 1309.
85. Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995; 92: 778-84.
86. 2+ ATPase in failing and nonfailing human myocardium. Circ Res 1994; 75: 434-42.
87. Gomez AM, Valdivia HH, Cheng H, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997; 276: 800-06.
88. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management Ann Intern Med 1992; 117: 502-10.